Takotsubo cardiomyopathy

Last updated: November 20, 2023

CME information and disclosurestoggle arrow icon

To see contributor disclosures related to this article, hover over this reference: [1]

Physicians may earn CME/MOC credit by searching for an answer to a clinical question on our platform, reading content in this article that addresses that question, and completing an evaluation in which they report the question and the impact of what has been learned on clinical practice.

AMBOSS designates this Internet point-of-care activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

For answers to questions about AMBOSS CME, including how to redeem CME/MOC credit, see "Tips and Links" at the bottom of this article.

Summarytoggle arrow icon

Takotsubo cardiomyopathy, also known as stress-induced cardiomyopathy, refers to acute, stress-induced, reversible dysfunction of the left ventricle. It is an uncommon but clinically significant cause of chest pain that can mimic acute coronary syndrome (ACS). Typically triggered by an extreme emotional stressor or severe illness, it is typically characterized by ballooning of the left ventricular wall, which can lead to chest pain and heart failure. While most cases fully resolve within a couple of weeks, patients can become critically ill, particularly if the disease causes left ventricular outflow tract obstruction (LVOT obstruction). As symptoms overlap with those seen in acute coronary syndrome, this condition should be excluded. See also cardiomyopathy for information on other cardiomyopathies.

Definitiontoggle arrow icon

  • Definition: acute, stress-induced; , reversible dysfunction of the left ventricle that can mimic acute coronary syndrome
  • Classification [2]
    • Primary form: Symptoms have led the patient to seek medical attention.
    • Secondary form : The patient is already seriously ill with another condition, meaning that the presentation may be more insidious.

Epidemiologytoggle arrow icon

  • 90% of affected individuals are postmenopausal women. [3]
  • More common in patients with preexisting mental illness [4]

Epidemiological data refers to the US, unless otherwise specified.

Etiologytoggle arrow icon

  • Triggers [3][4]
    • Intense emotional stress
      • The stress is usually negative (i.e., “broken heart syndrome”)
      • Less common: strong, positive emotions (i.e., “happy heart syndrome”)
    • Severe illness
    • Drugs
  • Pathophysiology: Emotional/physical stress → activation of the sympathetic nervous system → massive catecholamine discharge; → cardiotoxicity, multivessel spasms, and dysfunctionmyocardial stunning

Clinical featurestoggle arrow icon

Symptoms overlap with those seen in acute coronary syndrome (see “Clinical features” in acute coronary syndrome) and are characteristically preceded by a stressful event. [2][3]

Diagnosticstoggle arrow icon

The diagnosis of takotsubo cardiomyopathy requires left ventricle regional wall motion abnormalities (typically reversible) that extend beyond a single coronary artery distribution in the absence of obstructive coronary artery disease. It is extremely difficult to distinguish between takotsubo cardiomyopathy and acute coronary syndrome (ACS) on the basis of ECG and laboratory test findings alone; emergency coronary angiography is usually required to rule out ACS. [2][3]


Diagnostic criteria

Several diagnostic criteria are used to establish a diagnosis of stress-induced cardiomyopathy, including the revised Mayo Clinic criteria and the InterTAK diagnostic score.

InterTAK diagnostic score [6]
Variables Points assigned
Female sex 25
Emotional stress 24
Physical stress 13
Absence of ST depressions on ECG 12
Acute, former, or chronic psychiatric disorder 11
Acute, former, or chronic neurological disorder 9
Prolonged QTc interval 6


Laboratory studies [2][3]

ECG [3]

ECG is abnormal in > 95% of patients with takotsubo cardiomyopathy and usually shows ischemic changes. [2]


Differential diagnosestoggle arrow icon

The differential diagnoses listed here are not exhaustive.

Treatmenttoggle arrow icon

Treatment is mostly symptomatic and consists of supportive care and treatment of complications and comorbidities (e.g., acute heart failure, arrhythmias). It is critical to determine if LVOT obstruction (which is typically accompanied by mitral regurgitation) is present because inotropic support in these patients can precipitate worsening cardiac function and lead to cardiogenic shock. Consider empiric treatment for acute coronary syndrome until it can be ruled out. All patients should be admitted to the hospital for at least 48 hours of continuous telemetry.

Hemodynamically stable patients [2][10]

Hemodynamically unstable patients [2][10]

No LVOT obstruction [2]

LVOT obstruction (occurs in up to 25% of cases) [2]

LVOT obstruction further impairs LV systolic function and can be very difficult to treat. Inotropic support should be avoided, as this can precipitate cardiogenic shock in patients with LVOT obstruction.

Avoid inotropes, as they can worsen LVOT obstruction and precipitate cardiogenic shock.

Additional considerations for all patients [2][10]

Prognosistoggle arrow icon

Although most patients recover within days to weeks, relapses are not uncommon and in-hospital deaths occur especially in patients with complications leading to cardiogenic shock.

  • Recovery: within 1–2 weeks in most cases [2]
  • Recurrence rate: 2–4% per year [2]
  • In-hospital mortality: up to 5% [2]

Acute management checklisttoggle arrow icon

All patients

Hemodynamically stable patients

Hemodynamically unstable patients

Preventiontoggle arrow icon

  • Avoid triggers of physical and/or emotional stress.
  • Consider chronic beta blocker and/or ACE inhibitor/ARB therapy. [2][10]
  • Consider assessment (and referral to treatment) for mental health comorbidities. [2]

Referencestoggle arrow icon

  1. $Contributor Disclosures - Takotsubo cardiomyopathy. All of the relevant financial relationships listed for the following individuals have been mitigated: Jan Schlebes (medical editor, is a shareholder in Fresenius SE & Co KGaA). None of the other individuals in control of the content for this article reported relevant financial relationships with ineligible companies. For details, please review our full conflict of interest (COI) policy:.
  2. Medina de Chazal H, Del Buono MG, Keyser-Marcus L, et al. Stress Cardiomyopathy Diagnosis and Treatment. J Am Coll Cardiol. 2018; 72 (16): p.1955-1971.doi: 10.1016/j.jacc.2018.07.072 . | Open in Read by QxMD
  3. Pelliccia F, Kaski JC, Crea F, Camici PG. Pathophysiology of Takotsubo Syndrome. Circulation. 2017; 135 (24): p.2426-2441.doi: 10.1161/circulationaha.116.027121 . | Open in Read by QxMD
  4. Ghadri J-R, Wittstein IS, Prasad A, et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. Eur Heart J. 2018; 39 (22): p.2032-2046.doi: 10.1093/eurheartj/ehy076 . | Open in Read by QxMD
  5. Madhavan M, Prasad A. Proposed Mayo Clinic criteria for the diagnosis of Tako-Tsubo cardiomyopathy and long-term prognosis. Herz. 2010; 35 (4): p.240-244.doi: 10.1007/s00059-010-3339-x . | Open in Read by QxMD
  6. Ghadri JR, Cammann VL, Jurisic S, et al. A novel clinical score (InterTAK Diagnostic Score) to differentiate takotsubo syndrome from acute coronary syndrome: results from the International Takotsubo Registry. European Journal of Heart Failure. 2016; 19 (8): p.1036-1042.doi: 10.1002/ejhf.683 . | Open in Read by QxMD
  7. Brenner ZR, Powers J. Takotsubo cardiomyopathy. Heart Lung. 2008; 37 (1): p.1-7.doi: 10.1016/j.hrtlng.2006.12.003 . | Open in Read by QxMD
  8. Bratis K. Cardiac Magnetic Resonance in Takotsubo Syndrome. Eur Cardiol. 2017; 12 (1): p.58.doi: 10.15420/ecr.2017:7:2 . | Open in Read by QxMD
  9. Kohan AA, Levy Yeyati E, De Stefano L, et al. Usefulness of MRI in takotsubo cardiomyopathy: a review of the literature.. Cardiovasc Diagn Ther. 2014; 4 (2): p.138-46.doi: 10.3978/j.issn.2223-3652.2013.10.03 . | Open in Read by QxMD
  10. Komamura K. Takotsubo cardiomyopathy: Pathophysiology, diagnosis and treatment. World J Cardiol. 2014; 6 (7): p.602.doi: 10.4330/wjc.v6.i7.602 . | Open in Read by QxMD
  11. Nieminen MS, Fruhwald S, Heunks LM, et al. Levosimendan: current data, clinical use and future development.. Heart Lung Vessel. 2013; 5 (4): p.227-45.
  12. Antonini M, Stazi GV, Cirasa MT, Garotto G, Frustaci A. Efficacy of levosimendan in Takotsubo-related cardiogenic shock. Acta Anaesthesiol Scand. 2010; 54 (1): p.119-120.doi: 10.1111/j.1399-6576.2009.02105.x . | Open in Read by QxMD
  13. Isogai T, Matsui H, Tanaka H, Fushimi K, Yasunaga H. Early β-blocker use and in-hospital mortality in patients with Takotsubo cardiomyopathy. Heart. 2016; 102 (13): p.1029-1035.doi: 10.1136/heartjnl-2015-308712 . | Open in Read by QxMD
  14. Santoro F, Ieva R, Ferraretti A, et al. Hemodynamic Effects, Safety, and Feasibility of Intravenous Esmolol Infusion During Takotsubo Cardiomyopathy With Left Ventricular Outflow Tract Obstruction: Results From A Multicenter Registry. Cardiovasc Ther. 2016; 34 (3): p.161-166.doi: 10.1111/1755-5922.12182 . | Open in Read by QxMD
  15. Yoshioka T, Hashimoto A, Tsuchihashi K, et al. Clinical implications of midventricular obstruction and intravenous propranolol use in transient left ventricular apical ballooning (Tako-tsubo cardiomyopathy). Am Heart J. 2008; 155 (3): p.526.e1-526.e7.doi: 10.1016/j.ahj.2007.10.042 . | Open in Read by QxMD
  16. Migliore F, Bilato C, Isabella G, Iliceto S, Tarantini G. Haemodynamic effects of acute intravenous metoprolol in apical ballooning syndrome with dynamic left ventricular outflow tract obstruction. European Journal of Heart Failure. 2010; 12 (3): p.305-308.doi: 10.1093/eurjhf/hfp205 . | Open in Read by QxMD
  17. Akashi YJ, Goldstein DS, Barbaro G, Ueyama T. Takotsubo Cardiomyopathy. Circulation. 2008; 118 (25): p.2754-2762.doi: 10.1161/circulationaha.108.767012 . | Open in Read by QxMD
  18. Ghadri J-R, Wittstein IS, Prasad A, et al. International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. Eur Heart J. 2018; 39 (22): p.2047-2062.doi: 10.1093/eurheartj/ehy077 . | Open in Read by QxMD
  19. Mrozek S, Srairi M, Marhar F, et al. Successful treatment of inverted Takotsubo cardiomyopathy after severe traumatic brain injury with milrinone after dobutamine failure. Heart & Lung. 2016; 45 (5): p.406-408.doi: 10.1016/j.hrtlng.2016.06.007 . | Open in Read by QxMD

Icon of a lock3 free articles remaining

You have 3 free member-only articles left this month. Sign up and get unlimited access.
 Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer